Hypertension Management Guidelines for Adults

Blood Pressure Targets

• The American Heart Association/American College of Cardiology (AHA/ACC) recommends a universal treatment goal of <130/80 mm Hg for all adults. 1

Blood Pressure Classification (AHA/ACC)

• Normal: <120/<80 mm Hg 1
• Elevated: 120‑129/<80 mm Hg 1
• Stage 1 Hypertension: 130‑139/80‑89 mm Hg 1
• Stage 2 Hypertension: ≥140/≥90 mm Hg 1

Initiation of Pharmacotherapy

Immediate Initiation (AHA/ACC)

• Start medication (with lifestyle changes) for any adult with an average BP ≥140/90 mm Hg. 1
• Start medication for adults with BP ≥130/80 mm Hg who have any of the following: clinical cardiovascular disease, prior stroke, diabetes mellitus, chronic kidney disease, or a 10‑year cardiovascular risk ≥7.5 %. [1][2]

Delayed Initiation (AHA/ACC)

• For adults with BP ≥130/80 mm Hg and a 10‑year risk <7.5 %, defer medication for 3–6 months of lifestyle modification; initiate only if BP remains elevated. 1

Initial Medication Regimen

• For Stage 2 Hypertension (≥140/≥90 mm Hg), begin with a fixed‑dose single‑pill combination of two first‑line agents from different classes to improve adherence and accelerate control. 1
• The European Society of Cardiology (ESC) recommends upfront low‑dose combination therapy for confirmed hypertension (Stage 1 or higher) and monotherapy only for elevated BP without other indications. 2
• The AHA/ACC specifically supports dual therapy for Stage 2 hypertension. 1

First‑Line Medication Classes (ESC)

• ACE inhibitors 2
• Angiotensin receptor blockers (ARBs) 2
• Dihydropyridine calcium‑channel blockers (CCBs) 2

• Thiazide or thiazide‑like diuretics 2

• Safety caveat: Do not combine two renin‑angiotensin system blockers (ACE‑I + ARB). 2

Treatment Escalation Algorithm (ESC)

Step 1 – Dual Combination

• Initiate a single‑pill low‑dose combination of two first‑line agents. 2

Step 2 – Triple Combination

• If BP remains uncontrolled, advance to maximally tolerated triple therapy (RAS blocker + CCB + diuretic). 2

Step 3 – Resistant Hypertension

• After confirming adherence, add spironolactone as the preferred fourth agent. 2
• If spironolactone is intolerable, consider eplerenone, other mineralocorticoid‑receptor antagonists, or vasodilating β‑blockers (e.g., labetalol, carvedilol, nebivolol) when no contraindication exists. 2

Step 4 – Fifth‑Line Options

• Reserve the following agents for refractory cases: hydralazine, potassium‑sparing diuretics (e.g., amiloride, triamterene), centrally acting agents, α‑blockers, and minoxidil (last resort due to significant side effects). 2

Lifestyle Modifications (AHA/ACC)

• Encourage weight management, adherence to the DASH eating pattern, increased dietary potassium, stress management, and moderation or elimination of alcohol. 1

Blood Pressure Monitoring (AHA/ACC)

• Home BP monitoring combined with regular multidisciplinary team interactions using standardized protocols improves control rates. 1
• Avoid reliance on cuffless devices (e.g., smartwatches) until they demonstrate adequate precision and reliability. 1

Severe Hypertension Management (AHA/ACC)

• For severe hypertension (>180/120 mm Hg) without acute target‑organ damage, manage outpatient with timely initiation, reinstatement, or intensification of oral antihypertensive therapy rather than emergency department referral. 1

Team‑Based Care (AHA/ACC)

• A multidisciplinary team (physicians, pharmacists, nurse practitioners, nurses, physician assistants, dietitians, community health workers) effectively addresses medication access and structural barriers to achieve hypertension control. 1